Media Summary: Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. Elisa Agostinetto, MD, Istituto Clinico ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, ...
Sacituzumab Govitecan A Novel Treatment - Detailed Analysis & Overview
Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. Elisa Agostinetto, MD, Istituto Clinico ... Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, ... Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute evaluating the safety and effectiveness of ... Kevin Kalinsky, MD, MS, Emory University, Atlanta, GA, progression-free survival after next line of In patients with extensive stage small cell lung cancer (ES-SCLC),
There is a clear need for better therapies to Lisa Carey, MD, ScM, FASCO, from the University of North Carolina, Chapel Hill, NC, outlines the pivotal Phase III trial ASCENT ... In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III ... Dr. Isaacs Discusses Sacituzumab Govitecan in TNBC
